Efficacy and Safety of Medtronic 780G Automated Insulin Delivery System in Adults with Type 1 Diabetes and Gastroparesis
Zunera Tariq, MD, is enrolling participants age ≥18 years to evaluate efficacy (change in time spent in 70-180 mg/dL, TIR) and safety of an advanced automated insulin delivery (AID) system compared to usual care in adults with T1D and gastroparesis. This is a prospective, 12 week, open label, randomized clinical trial with 1:1 randomization to an intervention group using the study AID system versus usual care.
Clinical validation of islet autoantibody measurement in self-collected dried blood spot specimens
Viral Shah, MD, is enrolling newly diagnosed T1D patients (within 14 days of diagnosis) and patients with T1D diagnosis within the last two years that are on insulin treatment, into a study to compare accuracy of filter paper-based specimens to venous blood for islet autoantibody measurements. There is one study visit that can be done at bedside and will take approx. one hour, or can be a scheduled visit with the research team.
Randomized trial of ZT-01 (somatostatin receptor antagonist) on Nocturnal Hypoglycemia in Type 1 diabetes
Viral Shah, MD, is enrolling patients to test efficacy and safety of ZT-01 investigational drug on prevention of nocturnal hypoglycemia in adults with type 1 diabetes. Patients must have T1D for at least five years and time below range (TBR <54 for >1%), be over 18 years of age, and have BMI <33. Duration: three months and up to seven clinic visits. Patient will be randomized to receive drug/placebo injections every day for 30 days and 30 days off and again, 30 days (total of 90 days with 60 days of therapy and 30 days of washout.